Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

7.7K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.7K
Tumor Progression02:07

Tumor Progression

6.4K
Tumor progression is a phenomenon where the pre-formed tumor acquires successive mutations to become clinically more aggressive and malignant. In the 1950s, Foulds first described the stepwise progression of cancer cells through successive stages.
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
6.4K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Synergistic Inhibition of Colorectal Cancer Growth by Combined PI3K and COX-2 Blockade in Cell Lines and Patient-Derived Organoids.

Pharmaceutics·2026
Same author

Herpes Simplex Virus Type 1 (HSV-1) UL38 Capsid Protein: A Promising Target Against Viral Infection.

Viruses·2026
Same author

Sacituzumab Tirumotecan Across Gynecologic Malignancies: One Target, Multiple Diseases.

Current oncology reports·2026
Same author

CAFs and Endocrine Therapy Resistance in Hormone Receptor-Positive Breast Cancer.

International journal of molecular sciences·2026
Same author

Biologically Informed Treatment Approaches Toward Personalized Therapeutic Strategies in Lung Cancer.

International journal of molecular sciences·2026
Same author

Coupled-enzyme assay for MTAP activity in biological samples.

Analytical biochemistry·2026

Related Experiment Video

Updated: Jul 19, 2025

Development and Maintenance of a Preclinical Patient Derived Tumor Xenograft Model for the Investigation of Novel Anti-Cancer Therapies
09:29

Development and Maintenance of a Preclinical Patient Derived Tumor Xenograft Model for the Investigation of Novel Anti-Cancer Therapies

Published on: September 30, 2016

13.8K

Targeting KRAS in Colorectal Cancer: A Bench to Bedside Review.

Fernand Bteich1,2, Mahshid Mohammadi2,3, Terence Li2,3

  • 1Department of Medical Oncology, Montefiore Medical Center, Bronx, NY 10467, USA.

International Journal of Molecular Sciences
|August 12, 2023
PubMed
Summary

Targeting KRAS mutations in colorectal cancer (CRC) is advancing with new inhibitors. Combination therapies are crucial for overcoming resistance in KRAS-mutated CRC treatment.

Keywords:
KRAScancer therapeuticscolorectal cancertargeted therapy

More Related Videos

Isolation of Circulating Tumor Cells in an Orthotopic Mouse Model of Colorectal Cancer
06:19

Isolation of Circulating Tumor Cells in an Orthotopic Mouse Model of Colorectal Cancer

Published on: July 18, 2017

10.1K
A Multiplexed Luciferase-based Screening Platform for Interrogating Cancer-associated Signal Transduction in Cultured Cells
10:13

A Multiplexed Luciferase-based Screening Platform for Interrogating Cancer-associated Signal Transduction in Cultured Cells

Published on: July 3, 2013

11.2K

Related Experiment Videos

Last Updated: Jul 19, 2025

Development and Maintenance of a Preclinical Patient Derived Tumor Xenograft Model for the Investigation of Novel Anti-Cancer Therapies
09:29

Development and Maintenance of a Preclinical Patient Derived Tumor Xenograft Model for the Investigation of Novel Anti-Cancer Therapies

Published on: September 30, 2016

13.8K
Isolation of Circulating Tumor Cells in an Orthotopic Mouse Model of Colorectal Cancer
06:19

Isolation of Circulating Tumor Cells in an Orthotopic Mouse Model of Colorectal Cancer

Published on: July 18, 2017

10.1K
A Multiplexed Luciferase-based Screening Platform for Interrogating Cancer-associated Signal Transduction in Cultured Cells
10:13

A Multiplexed Luciferase-based Screening Platform for Interrogating Cancer-associated Signal Transduction in Cultured Cells

Published on: July 3, 2013

11.2K

Area of Science:

  • Oncology
  • Molecular Biology
  • Genetics

Background:

  • Colorectal cancer (CRC) is a complex disease with frequent KRAS mutations (up to 40%).
  • KRAS mutations drive tumorigenesis via the RAS/MAPK pathway, impacting proliferation and survival.
  • KRAS historically served as a prognostic and predictive biomarker, with limited direct therapeutic targeting until recently.

Purpose of the Study:

  • To review current understanding and findings on targeting KRAS mutations in CRC.
  • To explore mechanisms of resistance to KRAS inhibitors.
  • To discuss evolving treatment strategies for KRAS-mutated CRC.

Main Methods:

  • Review of recent preclinical and clinical research on KRAS inhibitors.
  • Analysis of adaptive resistance mechanisms in KRAS-mutated tumors.
  • Synthesis of current and emerging treatment strategies.

Main Results:

  • Several KRAS allele-specific inhibitors are in late-phase clinical trials.
  • Newer agents and targeting strategies are in early-phase development.
  • Combination therapies are essential due to robust adaptive resistance.

Conclusions:

  • Targeting KRAS mutations represents a significant advancement in CRC therapy.
  • Understanding and overcoming resistance mechanisms is critical for effective treatment.
  • Future CRC treatment will likely involve combination strategies for KRAS-mutated patients.